Characteristics and Outcomes of Patients Treated With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (The Mayo Clinic Experience) - PubMed

Characteristics and Outcomes of Patients Treated With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (The Mayo Clinic Experience)

Ohad Oren et al. Am J Cardiol. 2019.

Abstract

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors represent a novel addition to the lipid-lowering armamentarium. We attempted to characterize a real-world group of patients with a clinical indication for PCSK9 inhibitors and describe their clinical outcomes and adverse effect profile. A retrospective chart review was conducted, evaluating all patients referred to preventive cardiology at the Mayo Clinic (Minnesota) between September, 2015 and December, 2018 for management of severe dyslipidemia. A total of 222 patients were referred and a recommendation to start a PCSK9 inhibitor was given to 164 patients (73.9%). Of these, 28 patients (17.1%) declined the use of a PCSK9 inhibitor. A total of 136 previous authorizations were submitted. Of these applications, 96 (70.6%) were approved and 17 (12.5%) were rejected. The cohort's mean age was 64.1 years (range 39 to 91). High-intensity statins and ezetimibe were used in 50 (52.1%) and 80 (83.3%) of the treated patients. Mean pretreatment low-density lipoprotein cholesterol was 167.9 mg/dl. At a median follow-up of 19.0 months, the mean low-density lipoprotein reduction was 60.9% (range 0 to 90.3%). Higher low-density lipoprotein cholesterol percent reductions were seen in younger patients (p value 0.048), patients on high-intensity statins (p value 0.027), those with statin intolerance (p value 0.046), and individuals with a higher baseline triglycerides (p value 0.047). Two (2.1%) patients underwent coronary revascularization, and 1 (1.0%) patient was hospitalized for unstable angina. No cardiovascular deaths occurred. Adverse events were reported in 12 (12.5%) patients, and were all minor (injection site reactions, myalgias, and flu-like illness). In conclusion, our study shows an efficacy and safety profile that is concordant with previous investigations. The use of a standardized application form was associated with a high insurance approval rate.

Similar articles

• Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.

  Virani SS, Kennedy KF, Akeroyd JM, Morris PB, Bittner VA, Masoudi FA, Stone NJ, Petersen LA, Ballantyne CM. Virani SS, et al. Circ Cardiovasc Qual Outcomes. 2018 May;11(5):e004652. doi: 10.1161/CIRCOUTCOMES.118.004652. Circ Cardiovasc Qual Outcomes. 2018. PMID: 29748356 Free PMC article.

• Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.

  O'Keefe JH, DiNicolantonio JJ, Lavie CJ. O'Keefe JH, et al. Am J Cardiol. 2017 Feb 15;119(4):565-571. doi: 10.1016/j.amjcard.2016.11.001. Epub 2016 Nov 23. Am J Cardiol. 2017. PMID: 28081940

• A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.

  Khan SU, Talluri S, Riaz H, Rahman H, Nasir F, Bin Riaz I, Sattur S, Ahmed H, Kaluski E, Krasuski R. Khan SU, et al. Eur J Prev Cardiol. 2018 May;25(8):844-853. doi: 10.1177/2047487318766612. Epub 2018 Mar 23. Eur J Prev Cardiol. 2018. PMID: 29569492 Review.

• Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.

  Yadav K, Sharma M, Ferdinand KC. Yadav K, et al. Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30. Nutr Metab Cardiovasc Dis. 2016. PMID: 27352986 Review.

Cited by

• Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components.

  Turner RM, Pirmohamed M. Turner RM, et al. J Clin Med. 2019 Dec 20;9(1):22. doi: 10.3390/jcm9010022. J Clin Med. 2019. PMID: 31861911 Free PMC article. Review.

• PCSK9 Inhibitor Use and Outcomes Using Concomitant Lipid-Lowering Therapies in the Veterans Health Administration.

  Eloso J, Awad A, Zhao X, Cunningham FE, Zhang R, Dong D, Kelley C, Glassman PA, Aspinall SL. Eloso J, et al. Am J Med Open. 2023 Feb 18;9:100035. doi: 10.1016/j.ajmo.2023.100035. eCollection 2023 Jun. Am J Med Open. 2023. PMID: 39035055 Free PMC article.

• Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease.

  Smith A, Johnson D, Banks J, Keith SW, Karalis DG. Smith A, et al. J Clin Med. 2021 Aug 26;10(17):3828. doi: 10.3390/jcm10173828. J Clin Med. 2021. PMID: 34501275 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal